OncoTherapy Science, Inc.
TSE:4564.T
32 (JPY) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | OncoTherapy Science, Inc. |
Symbool | 4564.T |
Munteenheid | JPY |
Prijs | 32 |
Beurswaarde | 8,692,606,368 |
Dividendpercentage | 0% |
52-weken bereik | 15 - 64 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Junichi Shimada |
Website | https://www.oncotherapy.co.jp |
An error occurred while fetching data.
Over OncoTherapy Science, Inc.
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (JPY)
Cijfers zijn in miljoenen (JPY)